Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708

Article  PubMed  Google Scholar 

DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61:409–418. https://doi.org/10.3322/caac.20134

Article  PubMed  Google Scholar 

Daly MB, Pal T, Berry MP Genetic/Familial High-Risk Assessment: Breast, Ovarian, and, Pancreatic et al (2021) Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:77–102. https://doi.org/10.6004/jnccn.2021.0001

Bedrosian I, Somerfield MR, Achatz MI et al (2024) Germline testing in patients with breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol JCO 2302225. https://doi.org/10.1200/JCO.23.02225

Infante M, Arranz-Ledo M, Lastra E et al (2024) Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations. Clin Chim Acta 552:117695. https://doi.org/10.1016/j.cca.2023.117695

Article  CAS  PubMed  Google Scholar 

Farokhi Boroujeni S, Rodriguez G, Galpin K et al (2023) BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy. J Ovarian Res 16:231. https://doi.org/10.1186/s13048-023-01313-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lynch HT, Casey MJ, Snyder CL et al (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3:97–137. https://doi.org/10.1016/j.molonc.2009.02.004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Serova OM, Mazoyer S, Puget N et al (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60:486–495

CAS  PubMed  PubMed Central  Google Scholar 

Sung P-L, Wen K-C, Chen Y-J et al (2017) The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: from BRCA1/2 to multi-gene panels. PLoS ONE 12:e0185615. https://doi.org/10.1371/journal.pone.0185615

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minion LE, Dolinsky JS, Chase DM et al (2015) Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol Oncol 137:86–92. https://doi.org/10.1016/j.ygyno.2015.01.537

Article  CAS  PubMed  Google Scholar 

Lin P-H, Tien Y-W, Cheng W-F et al (2023) Diverse genetic spectrum among patients who met the criteria of hereditary breast, ovarian and pancreatic cancer syndrome. J Gynecol Oncol 34:e66. https://doi.org/10.3802/jgo.2023.34.e66

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demir S, Tozkir H, Gurkan H et al (2020) Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey. J BUON 25:1337–1347

PubMed  Google Scholar 

Morgan RD, Burghel GJ, Flaum N et al (2019) Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. J Med Genet 56:301–307. https://doi.org/10.1136/jmedgenet-2018-105792

Article  CAS  PubMed  Google Scholar 

Flaum N, Morgan RD, Burghel GJ et al (2020) Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Eur J Hum Genet 28:1541–1547. https://doi.org/10.1038/s41431-020-0692-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Metcalfe KA, Fan I, McLaughlin J et al (2009) Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol 112:68–72. https://doi.org/10.1016/j.ygyno.2008.10.007

Article  PubMed  Google Scholar 

Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654–2663. https://doi.org/10.1200/JCO.2011.39.8545

Article  CAS  PubMed  PubMed Central  Google Scholar 

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer - PubMed. https://pubmed.ncbi.nlm.nih.gov/38072854/. Accessed 9 Jan 2024

Shah S, Cheung A, Kutka M et al (2022) Epithelial ovarian Cancer: providing evidence of predisposition genes. Int J Environ Res Public Health 19:8113. https://doi.org/10.3390/ijerph19138113

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87. https://doi.org/10.1093/jnci/djn442

Article  CAS  PubMed  PubMed Central  Google Scholar 

US Preventive Services Task Force, Owens DK, Davidson KW et al (2019) Risk Assessment, genetic counseling, and genetic testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 322:652–665. https://doi.org/10.1001/jama.2019.10987

Article  Google Scholar 

Domchek S, Robson M (2019) Broadening Criteria for BRCA1/2 evaluation: placing the USPSTF recommendation in Context. JAMA 322:619–621. https://doi.org/10.1001/jama.2019.9688

Article  PubMed  Google Scholar 

Eleje GU, Eke AC, Ezebialu IU et al (2018) Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev 8:CD012464. https://doi.org/10.1002/14651858.CD012464.pub2

Article  PubMed  Google Scholar 

Li C, Du C, Wang Y et al (2023) Risk, molecular subtype and prognosis of second primary breast cancer: an analysis based on first primary cancers. Am J Cancer Res 13:3203–3220

CAS  PubMed  PubMed Central  Google Scholar 

Comes MC, Arezzo F, Cormio G et al (2023) An explainable machine learning ensemble model to predict the risk of ovarian cancer in BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy. Front Oncol 13:1181792. https://doi.org/10.3389/fonc.2023.1181792

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ueki A, Yoshida R, Kosaka T, Matsubayashi H (2023) Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan. J Hum Genet 68:517–526. https://doi.org/10.1038/s10038-023-01153-1

Article  CAS  PubMed  Google Scholar 

Hd N, M P, B Z, et al (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 160. https://doi.org/10.7326/M13-1684.

Nelson HD, Pappas M, Cantor A et al (2019) Risk Assessment, genetic counseling, and genetic testing for BRCA-Related Cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 322:666–685. https://doi.org/10.1001/jama.2019.8430

Article  PubMed  Google Scholar 

McGrail DJ, Li Y, Smith RS et al (2023) Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins. Cell Rep Med 4:101255. https://doi.org/10.1016/j.xcrm.2023.101255

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans EC, Matteson KA, Orejuela FJ et al (2016) Salpingo-oophorectomy at the time of Benign Hysterectomy: a systematic review. Obstet Gynecol 128:476–485. https://doi.org/10.1097/AOG.0000000000001592

Article  PubMed  Google Scholar 

Parker WH, Feskanich D, Broder MS et al (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121:709–716. https://doi.org/10.1097/AOG.0b013e3182864350

Article  PubMed  PubMed Central  Google Scholar 

Howard BV, Kuller L, Langer R et al (2005) Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the women’s Health Initiative Observational Study. Circulation 111:1462–1470. https://doi.org/10.1161/01.CIR.0000159344.21672.FD

Article  PubMed  Google Scholar 

Mielke MM, Kapoor E, Geske JR et al (2023) Long-term effects of premenopausal bilateral oophorectomy with or without hysterectomy on physical aging and chronic medical conditions.